Nanotech Investing Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Nanotech Investing Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
Nanotech Investing Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
Nanotech Investing Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Nanotech Investing Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
